EMA Authorised: Lysodren (mitotane) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

EMA authorised marketing of Lysodren (mitotane) by Esteve Pharmaceuticals, S.A. for adrenal cortex neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Cortex Neoplasms
• Adrenocortical Carcinoma

Drugs mentioned

• LYSODREN (MITOTANE)

Snippet

Status: Authorised. Therapeutic area: Adrenal Cortex Neoplasms. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 13/02/2026